Form 4: Aprea Therapeutics CEO Oren Gilad Acquires Shares

Aprea Therapeutics' CEO, Oren Gilad, recently acquired 250 shares of common stock and disclaims beneficial ownership of shares held by his children.

Summary

• On October 15, 2024, Oren Gilad, the President and CEO of Aprea Therapeutics, acquired 250 shares of common stock at a price of $2.9 per share.
• Following this transaction, Gilad directly owns 332,895 shares of Aprea Therapeutics.
• Gilad also disclaims beneficial ownership of 1,200 shares held by his daughter and 600 shares held by his son.

Sentiment

Score: 5

Explanation: Neutral sentiment as it is a routine disclosure of insider trading activity. The purchase is small and the disclaimer of ownership of family member's shares is standard.

Positives

• The CEO's purchase of shares may signal confidence in the company's future prospects.

Management Comments

• The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Industry Context

Insider trading activity is closely monitored by regulators and investors as it can provide insights into a company's performance and future prospects. Form 4 filings are a routine part of this monitoring process.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates